Therapeutic Implications of GIPC1 Silencing in Cancer

DSpace/Manakin Repository

Therapeutic Implications of GIPC1 Silencing in Cancer

Citable link to this page

. . . . . .

Title: Therapeutic Implications of GIPC1 Silencing in Cancer
Author: Chittenden, Thomas W.; Pak, Jane; Rubio, Renee; Holton, Kristina; Prendergast, Niall; Glinskii, Vladimir; Schwede, Mathew; Howe, Eleanor A.; Aryee, Martin; Sultana, Razvan; Lanahan, Anthony A.; Holmes, Chris; Cheng, Hailing; Cai, Yi; Culhane, Aedin; Bentink, Stefan; Mar, Jessica Cara; Taylor, Jennifer; Hahn, William C.; Zhao, Jean J.; Iglehart, James Dirk; Quackenbush, John

Note: Order does not necessarily reflect citation order of authors.

Citation: Chittenden, Thomas W., Jane Pak, Renee Rubio, Hailing Cheng, Kristina Holton, Niall Prendergast, Vladimir Glinskii, et al. 2010. Therapeutic Implications of GIPC1 Silencing in Cancer. PLoS ONE 5(12): e15581.
Full Text & Related Files:
Abstract: GIPC1 is a cytoplasmic scaffold protein that interacts with numerous receptor signaling complexes, and emerging evidence suggests that it plays a role in tumorigenesis. GIPC1 is highly expressed in a number of human malignancies, including breast, ovarian, gastric, and pancreatic cancers. Suppression of GIPC1 in human pancreatic cancer cells inhibits in vivo tumor growth in immunodeficient mice. To better understand GIPC1 function, we suppressed its expression in human breast and colorectal cancer cell lines and human mammary epithelial cells (HMECs) and assayed both gene expression and cellular phenotype. Suppression of GIPC1 promotes apoptosis in MCF-7, MDA-MD231, SKBR-3, SW480, and SW620 cells and impairs anchorage-independent colony formation of HMECs. These observations indicate GIPC1 plays an essential role in oncogenic transformation, and its expression is necessary for the survival of human breast and colorectal cancer cells. Additionally, a GIPC1 knock-down gene signature was used to interrogate publically available breast and ovarian cancer microarray datasets. This GIPC1 signature statistically correlates with a number of breast and ovarian cancer phenotypes and clinical outcomes, including patient survival. Taken together, these data indicate that GIPC1 inhibition may represent a new target for therapeutic development for the treatment of human cancers.
Published Version: doi:10.1371/journal.pone.0015581
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3012716/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:4874475

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters